However, due to the diversity of tumor microenvironment and the dynamic changes in PD-1/PD-L1 expression resulting from concomitant treatments (Lim et al., 2016; Thomas et al., 2019), the spatial and temporal limitations of IHC analysis lead to uncertainty in decision-making for carrying out IBT. Here, CD274 is linked to neoplasm.